CYP2D6与CYP2C8药物遗传学及药物相互作用预测GIST患者伊马替尼血浆暴露
该前瞻性临床试验纳入33例每日口服伊马替尼400 mg的GIST患者,采集161份血浆样本,分析伊马替尼代谢相关细胞色素(CYP3A4、CYP3A5、CYP2D6、CYP2C9、CYP2C19、CYP2C8)的基因活性评分(GAS)与伊马替尼及去甲伊马替尼谷浓度的关联,并评估药物相互作用(DDI)的影响。CYP2D6 DDI调整后GAS仍可预测伊马替尼暴露。
要点
- CYP2D6 GAS及代谢者状态与伊马替尼及其代谢物谷浓度相关。
- CYP2D6慢/中间代谢者代谢比低于正常代谢者,CYP2C8*3携带者代谢比升高。
- DDI调整后CYP2D6 GAS仍预测伊马替尼暴露,可辅助识别暴露不足或过高风险患者。
核心结论
- CYP2D6在伊马替尼药代动力学中起主要作用,CYP2C8等其他因素也可能影响伊马替尼暴露。
- 上述发现有助于筛选更易发生伊马替尼暴露不足或过高的患者,作为个体化治疗和强化监测的候选人群。
研究设计与样本
- 前瞻性临床试验,纳入33例每日口服伊马替尼400 mg的GIST患者,连续采集血浆样本。
- 采用液相色谱-串联质谱(LC-MS/MS)定量伊马替尼和去甲伊马替尼谷浓度(Ctrough),共测定161份血浆样本。
- 识别对伊马替尼代谢细胞色素有功能影响的基因多态性,计算每个基因的基因活性评分(GAS),并生成DDI调整后的GAS。
主要发现
- CYP2D6 GAS及基于基因型的代谢者状态与伊马替尼及(伊马替尼+去甲伊马替尼)Ctrough相关。
- CYP2C9代谢者状态与代谢比呈负相关,其效应可能由CYP2C9*2与CYP2C8*3之间的连锁不平衡驱动。
- CYP2D6 DDI调整后GAS仍可预测伊马替尼暴露。
临床怎么用
- 对于接受固定剂量伊马替尼治疗的GIST患者,可考虑CYP2D6基因型及DDI调整后GAS以识别暴露不足或过高风险。
- 对CYP2D6慢代谢或中间代谢者、CYP2C8*3携带者等高危患者,可强化治疗药物监测和个体化随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Patients on treatment with oral fixed dose imatinib are frequently under- or overexposed to the drug. We investigated the association between the gene activity score (GAS) of imatinib-metabolizing cytochromes (CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19, CYP2C8) and imatinib and nor-imatinib exposure. We also investigated the impact of concurrent drug-drug-interactions (DDIs) on the association between GAS and imatinib exposure. METHODS: Serial plasma samples were collected from 33 GIST patients treated with imatinib 400 mg daily within a prospective clinical trial. Imatinib and nor-imatinib Ctrough were quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Genetic polymorphisms with a functional impact on imatinib-metabolizing cytochromes were identified and a GAS was calculated for each gene. A DDI-adjusted GAS was also generated. RESULTS: Imatinib and nor-imatinib Ctrough were measured in 161 plasma samples. CYP2D6 GAS and metabolizer status based on genotype were associated with imatinib and (imatinib + nor-imatinib) Ctrough . CYP2D6 poor and intermediate metabolizers were predicted to have a lower nor-imatinib/imatinib metabolic ratio than normal metabolizers (0.197 and 0.193 vs. 0.247, P = .0205), whereas CYP2C8*3 carriers had a higher ratio than CYP2C8*1/*1 patients (0.263 vs. 0.201, P = .0220). CYP2C9 metabolizer status was inversely related to the metabolic ratio with an effect probably driven by the linkage disequilibrium between CYP2C9*2 and CYP2C8*3. The CYP2D6 DDI-adjusted GAS was still predictive of imatinib exposure. CONCLUSIONS: These findings highlight that CYP2D6 plays a major role in imatinib pharmacokinetics, but other players (i.e., CYP2C8) may influence imatinib exposure. These findings could drive the selection of patients more susceptible to imatinib under- or overexposure who could be candidates for personalized treatment and intensified monitoring strategies.
引用
- Dalle Fratte C, Gagno S, Roncato R, et al. CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients. Br J Clin Pharmacol. 2022. PMID: 36178950. doi:10.1111/bcp.15551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。